IMMUNOMODULATORY EFFECTS OF BESTIM IN PATIENTS WITH PEPTIC ULCER

<strong<Abstract. </strong<Ulcer disease is accompanied by all immune responses with the development of secondary immune deficiency. We studied 92 males with peptic ulcer having positive tests for Helicobacter pylori (24 gastric ulcer, mean age 44,7±1,97 and 68 duodenal ulcer, mean age 3...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	A. G. Tkacheva [verfasserIn] A. I. Dolgushina [verfasserIn] K. V. Nikushina [verfasserIn] A. S. Simbirtsev [verfasserIn]

Format:	E-Artikel
Sprache:	Russisch

Erschienen:	2014

Schlagwörter:	Bestim immunity Т–helpers Helicobacter pylori gastric ulcer disease

Übergeordnetes Werk:	In: Медицинская иммунология - St. Petersburg branch of the Russian Association of Allergologists and Clinical Immunologists, 2015, 7(2014), 5–6, Seite 611-616
Übergeordnetes Werk:	volume:7 ; year:2014 ; number:5–6 ; pages:611-616

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc Journal toc

DOI / URN:	10.15789/1563-0625-2005-5–6-611-616

Katalog-ID:	DOAJ00064529X

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ00064529X
003	DE-627
005	20230310194208.0
007	cr uuu---uuuuu
008	230225s2014 xx \|\|\|\|\|o 00\| \|\|rus c
024	7		\|a 10.15789/1563-0625-2005-5–6-611-616 \|2 doi
035			\|a (DE-627)DOAJ00064529X
035			\|a (DE-599)DOAJd573419000114b45bf6a45334ccfce5a
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a rus
050		0	\|a RC581-607
100	0		\|a A. G. Tkacheva \|e verfasserin \|4 aut
245	1	0	\|a IMMUNOMODULATORY EFFECTS OF BESTIM IN PATIENTS WITH PEPTIC ULCER
264		1	\|c 2014
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a <strong<Abstract. </strong<Ulcer disease is accompanied by all immune responses with the development of secondary immune deficiency. We studied 92 males with peptic ulcer having positive tests for Helicobacter pylori (24 gastric ulcer, mean age 44,7±1,97 and 68 duodenal ulcer, mean age 31,5±1,71). A half of the patients used only basis antiulcer treatment. 46 patients used bestim in the dose100 mcg per day intramusculare for a 5 days with antisecretory and antihelicobacter drugs. The addition of bestim normalized cellular immunity: count of T-lymphocytes rose from 20,52±0,89% to 31,4±1,16% (p<0,05; confidence interval [CI]: 2,67-11,63). A positive trend in the number of T-lymphocytes was accompanied with increasing of T-helpers from 17,33±0,89% to 24,82±1,11% (p<0,05; 95%CI: 1,72-8,47). In the course of the treatment we observed normalization of monocytes number, an increase of neutrophils activity in blood (p<0,05; 95%CI: 2,35-15,64). We demonstrated decrease in IL-8 production and increase in IFN gamma production. Thus, the application of a new drug Bestim in the combined antiulcer treatment affects the immune state of the patients favourably. It decreases the inflammatory effect in the stomach and duodenal mucosa, it precipitate regress of clinical symptoms and healing of the ulcer.
650		4	\|a Bestim
650		4	\|a immunity
650		4	\|a Т–helpers
650		4	\|a Helicobacter pylori
650		4	\|a gastric ulcer disease
653		0	\|a Immunologic diseases. Allergy
700	0		\|a A. I. Dolgushina \|e verfasserin \|4 aut
700	0		\|a K. V. Nikushina \|e verfasserin \|4 aut
700	0		\|a A. S. Simbirtsev \|e verfasserin \|4 aut
773	0	8	\|i In \|t Медицинская иммунология \|d St. Petersburg branch of the Russian Association of Allergologists and Clinical Immunologists, 2015 \|g 7(2014), 5–6, Seite 611-616 \|w (DE-627)1735558133 \|x 2313741X \|7 nnns
773	1	8	\|g volume:7 \|g year:2014 \|g number:5–6 \|g pages:611-616
856	4	0	\|u https://doi.org/10.15789/1563-0625-2005-5–6-611-616 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/d573419000114b45bf6a45334ccfce5a \|z kostenfrei
856	4	0	\|u http://mimmun.ru/index.php/mimmun/article/view/653 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/1563-0625 \|y Journal toc \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2313-741X \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 7 \|j 2014 \|e 5–6 \|h 611-616

Indexfelder

author_variant	a g t agt a i d aid k v n kvn a s s ass
matchkey_str	article:2313741X:2014----::muoouaoyfetobsiiptetw
hierarchy_sort_str	2014
callnumber-subject-code	RC
publishDate	2014
allfields	10.15789/1563-0625-2005-5–6-611-616 doi (DE-627)DOAJ00064529X (DE-599)DOAJd573419000114b45bf6a45334ccfce5a DE-627 ger DE-627 rakwb rus RC581-607 A. G. Tkacheva verfasserin aut IMMUNOMODULATORY EFFECTS OF BESTIM IN PATIENTS WITH PEPTIC ULCER 2014 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <strong<Abstract. </strong<Ulcer disease is accompanied by all immune responses with the development of secondary immune deficiency. We studied 92 males with peptic ulcer having positive tests for Helicobacter pylori (24 gastric ulcer, mean age 44,7±1,97 and 68 duodenal ulcer, mean age 31,5±1,71). A half of the patients used only basis antiulcer treatment. 46 patients used bestim in the dose100 mcg per day intramusculare for a 5 days with antisecretory and antihelicobacter drugs. The addition of bestim normalized cellular immunity: count of T-lymphocytes rose from 20,52±0,89% to 31,4±1,16% (p<0,05; confidence interval [CI]: 2,67-11,63). A positive trend in the number of T-lymphocytes was accompanied with increasing of T-helpers from 17,33±0,89% to 24,82±1,11% (p<0,05; 95%CI: 1,72-8,47). In the course of the treatment we observed normalization of monocytes number, an increase of neutrophils activity in blood (p<0,05; 95%CI: 2,35-15,64). We demonstrated decrease in IL-8 production and increase in IFN gamma production. Thus, the application of a new drug Bestim in the combined antiulcer treatment affects the immune state of the patients favourably. It decreases the inflammatory effect in the stomach and duodenal mucosa, it precipitate regress of clinical symptoms and healing of the ulcer. Bestim immunity Т–helpers Helicobacter pylori gastric ulcer disease Immunologic diseases. Allergy A. I. Dolgushina verfasserin aut K. V. Nikushina verfasserin aut A. S. Simbirtsev verfasserin aut In Медицинская иммунология St. Petersburg branch of the Russian Association of Allergologists and Clinical Immunologists, 2015 7(2014), 5–6, Seite 611-616 (DE-627)1735558133 2313741X nnns volume:7 year:2014 number:5–6 pages:611-616 https://doi.org/10.15789/1563-0625-2005-5–6-611-616 kostenfrei https://doaj.org/article/d573419000114b45bf6a45334ccfce5a kostenfrei http://mimmun.ru/index.php/mimmun/article/view/653 kostenfrei https://doaj.org/toc/1563-0625 Journal toc kostenfrei https://doaj.org/toc/2313-741X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 7 2014 5–6 611-616
spelling	10.15789/1563-0625-2005-5–6-611-616 doi (DE-627)DOAJ00064529X (DE-599)DOAJd573419000114b45bf6a45334ccfce5a DE-627 ger DE-627 rakwb rus RC581-607 A. G. Tkacheva verfasserin aut IMMUNOMODULATORY EFFECTS OF BESTIM IN PATIENTS WITH PEPTIC ULCER 2014 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <strong<Abstract. </strong<Ulcer disease is accompanied by all immune responses with the development of secondary immune deficiency. We studied 92 males with peptic ulcer having positive tests for Helicobacter pylori (24 gastric ulcer, mean age 44,7±1,97 and 68 duodenal ulcer, mean age 31,5±1,71). A half of the patients used only basis antiulcer treatment. 46 patients used bestim in the dose100 mcg per day intramusculare for a 5 days with antisecretory and antihelicobacter drugs. The addition of bestim normalized cellular immunity: count of T-lymphocytes rose from 20,52±0,89% to 31,4±1,16% (p<0,05; confidence interval [CI]: 2,67-11,63). A positive trend in the number of T-lymphocytes was accompanied with increasing of T-helpers from 17,33±0,89% to 24,82±1,11% (p<0,05; 95%CI: 1,72-8,47). In the course of the treatment we observed normalization of monocytes number, an increase of neutrophils activity in blood (p<0,05; 95%CI: 2,35-15,64). We demonstrated decrease in IL-8 production and increase in IFN gamma production. Thus, the application of a new drug Bestim in the combined antiulcer treatment affects the immune state of the patients favourably. It decreases the inflammatory effect in the stomach and duodenal mucosa, it precipitate regress of clinical symptoms and healing of the ulcer. Bestim immunity Т–helpers Helicobacter pylori gastric ulcer disease Immunologic diseases. Allergy A. I. Dolgushina verfasserin aut K. V. Nikushina verfasserin aut A. S. Simbirtsev verfasserin aut In Медицинская иммунология St. Petersburg branch of the Russian Association of Allergologists and Clinical Immunologists, 2015 7(2014), 5–6, Seite 611-616 (DE-627)1735558133 2313741X nnns volume:7 year:2014 number:5–6 pages:611-616 https://doi.org/10.15789/1563-0625-2005-5–6-611-616 kostenfrei https://doaj.org/article/d573419000114b45bf6a45334ccfce5a kostenfrei http://mimmun.ru/index.php/mimmun/article/view/653 kostenfrei https://doaj.org/toc/1563-0625 Journal toc kostenfrei https://doaj.org/toc/2313-741X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 7 2014 5–6 611-616
allfields_unstemmed	10.15789/1563-0625-2005-5–6-611-616 doi (DE-627)DOAJ00064529X (DE-599)DOAJd573419000114b45bf6a45334ccfce5a DE-627 ger DE-627 rakwb rus RC581-607 A. G. Tkacheva verfasserin aut IMMUNOMODULATORY EFFECTS OF BESTIM IN PATIENTS WITH PEPTIC ULCER 2014 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <strong<Abstract. </strong<Ulcer disease is accompanied by all immune responses with the development of secondary immune deficiency. We studied 92 males with peptic ulcer having positive tests for Helicobacter pylori (24 gastric ulcer, mean age 44,7±1,97 and 68 duodenal ulcer, mean age 31,5±1,71). A half of the patients used only basis antiulcer treatment. 46 patients used bestim in the dose100 mcg per day intramusculare for a 5 days with antisecretory and antihelicobacter drugs. The addition of bestim normalized cellular immunity: count of T-lymphocytes rose from 20,52±0,89% to 31,4±1,16% (p<0,05; confidence interval [CI]: 2,67-11,63). A positive trend in the number of T-lymphocytes was accompanied with increasing of T-helpers from 17,33±0,89% to 24,82±1,11% (p<0,05; 95%CI: 1,72-8,47). In the course of the treatment we observed normalization of monocytes number, an increase of neutrophils activity in blood (p<0,05; 95%CI: 2,35-15,64). We demonstrated decrease in IL-8 production and increase in IFN gamma production. Thus, the application of a new drug Bestim in the combined antiulcer treatment affects the immune state of the patients favourably. It decreases the inflammatory effect in the stomach and duodenal mucosa, it precipitate regress of clinical symptoms and healing of the ulcer. Bestim immunity Т–helpers Helicobacter pylori gastric ulcer disease Immunologic diseases. Allergy A. I. Dolgushina verfasserin aut K. V. Nikushina verfasserin aut A. S. Simbirtsev verfasserin aut In Медицинская иммунология St. Petersburg branch of the Russian Association of Allergologists and Clinical Immunologists, 2015 7(2014), 5–6, Seite 611-616 (DE-627)1735558133 2313741X nnns volume:7 year:2014 number:5–6 pages:611-616 https://doi.org/10.15789/1563-0625-2005-5–6-611-616 kostenfrei https://doaj.org/article/d573419000114b45bf6a45334ccfce5a kostenfrei http://mimmun.ru/index.php/mimmun/article/view/653 kostenfrei https://doaj.org/toc/1563-0625 Journal toc kostenfrei https://doaj.org/toc/2313-741X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 7 2014 5–6 611-616
allfieldsGer	10.15789/1563-0625-2005-5–6-611-616 doi (DE-627)DOAJ00064529X (DE-599)DOAJd573419000114b45bf6a45334ccfce5a DE-627 ger DE-627 rakwb rus RC581-607 A. G. Tkacheva verfasserin aut IMMUNOMODULATORY EFFECTS OF BESTIM IN PATIENTS WITH PEPTIC ULCER 2014 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <strong<Abstract. </strong<Ulcer disease is accompanied by all immune responses with the development of secondary immune deficiency. We studied 92 males with peptic ulcer having positive tests for Helicobacter pylori (24 gastric ulcer, mean age 44,7±1,97 and 68 duodenal ulcer, mean age 31,5±1,71). A half of the patients used only basis antiulcer treatment. 46 patients used bestim in the dose100 mcg per day intramusculare for a 5 days with antisecretory and antihelicobacter drugs. The addition of bestim normalized cellular immunity: count of T-lymphocytes rose from 20,52±0,89% to 31,4±1,16% (p<0,05; confidence interval [CI]: 2,67-11,63). A positive trend in the number of T-lymphocytes was accompanied with increasing of T-helpers from 17,33±0,89% to 24,82±1,11% (p<0,05; 95%CI: 1,72-8,47). In the course of the treatment we observed normalization of monocytes number, an increase of neutrophils activity in blood (p<0,05; 95%CI: 2,35-15,64). We demonstrated decrease in IL-8 production and increase in IFN gamma production. Thus, the application of a new drug Bestim in the combined antiulcer treatment affects the immune state of the patients favourably. It decreases the inflammatory effect in the stomach and duodenal mucosa, it precipitate regress of clinical symptoms and healing of the ulcer. Bestim immunity Т–helpers Helicobacter pylori gastric ulcer disease Immunologic diseases. Allergy A. I. Dolgushina verfasserin aut K. V. Nikushina verfasserin aut A. S. Simbirtsev verfasserin aut In Медицинская иммунология St. Petersburg branch of the Russian Association of Allergologists and Clinical Immunologists, 2015 7(2014), 5–6, Seite 611-616 (DE-627)1735558133 2313741X nnns volume:7 year:2014 number:5–6 pages:611-616 https://doi.org/10.15789/1563-0625-2005-5–6-611-616 kostenfrei https://doaj.org/article/d573419000114b45bf6a45334ccfce5a kostenfrei http://mimmun.ru/index.php/mimmun/article/view/653 kostenfrei https://doaj.org/toc/1563-0625 Journal toc kostenfrei https://doaj.org/toc/2313-741X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 7 2014 5–6 611-616
allfieldsSound	10.15789/1563-0625-2005-5–6-611-616 doi (DE-627)DOAJ00064529X (DE-599)DOAJd573419000114b45bf6a45334ccfce5a DE-627 ger DE-627 rakwb rus RC581-607 A. G. Tkacheva verfasserin aut IMMUNOMODULATORY EFFECTS OF BESTIM IN PATIENTS WITH PEPTIC ULCER 2014 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <strong<Abstract. </strong<Ulcer disease is accompanied by all immune responses with the development of secondary immune deficiency. We studied 92 males with peptic ulcer having positive tests for Helicobacter pylori (24 gastric ulcer, mean age 44,7±1,97 and 68 duodenal ulcer, mean age 31,5±1,71). A half of the patients used only basis antiulcer treatment. 46 patients used bestim in the dose100 mcg per day intramusculare for a 5 days with antisecretory and antihelicobacter drugs. The addition of bestim normalized cellular immunity: count of T-lymphocytes rose from 20,52±0,89% to 31,4±1,16% (p<0,05; confidence interval [CI]: 2,67-11,63). A positive trend in the number of T-lymphocytes was accompanied with increasing of T-helpers from 17,33±0,89% to 24,82±1,11% (p<0,05; 95%CI: 1,72-8,47). In the course of the treatment we observed normalization of monocytes number, an increase of neutrophils activity in blood (p<0,05; 95%CI: 2,35-15,64). We demonstrated decrease in IL-8 production and increase in IFN gamma production. Thus, the application of a new drug Bestim in the combined antiulcer treatment affects the immune state of the patients favourably. It decreases the inflammatory effect in the stomach and duodenal mucosa, it precipitate regress of clinical symptoms and healing of the ulcer. Bestim immunity Т–helpers Helicobacter pylori gastric ulcer disease Immunologic diseases. Allergy A. I. Dolgushina verfasserin aut K. V. Nikushina verfasserin aut A. S. Simbirtsev verfasserin aut In Медицинская иммунология St. Petersburg branch of the Russian Association of Allergologists and Clinical Immunologists, 2015 7(2014), 5–6, Seite 611-616 (DE-627)1735558133 2313741X nnns volume:7 year:2014 number:5–6 pages:611-616 https://doi.org/10.15789/1563-0625-2005-5–6-611-616 kostenfrei https://doaj.org/article/d573419000114b45bf6a45334ccfce5a kostenfrei http://mimmun.ru/index.php/mimmun/article/view/653 kostenfrei https://doaj.org/toc/1563-0625 Journal toc kostenfrei https://doaj.org/toc/2313-741X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 7 2014 5–6 611-616
language	Russian
source	In Медицинская иммунология 7(2014), 5–6, Seite 611-616 volume:7 year:2014 number:5–6 pages:611-616
sourceStr	In Медицинская иммунология 7(2014), 5–6, Seite 611-616 volume:7 year:2014 number:5–6 pages:611-616
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Bestim immunity Т–helpers Helicobacter pylori gastric ulcer disease Immunologic diseases. Allergy
isfreeaccess_bool	true
container_title	Медицинская иммунология
authorswithroles_txt_mv	A. G. Tkacheva @@aut@@ A. I. Dolgushina @@aut@@ K. V. Nikushina @@aut@@ A. S. Simbirtsev @@aut@@
publishDateDaySort_date	2014-01-01T00:00:00Z
hierarchy_top_id	1735558133
id	DOAJ00064529X
language_de	russisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ00064529X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230310194208.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230225s2014 xx \|\|\|\|\|o 00\| \|\|rus c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.15789/1563-0625-2005-5–6-611-616</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ00064529X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJd573419000114b45bf6a45334ccfce5a</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC581-607</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">A. G. Tkacheva</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">IMMUNOMODULATORY EFFECTS OF BESTIM IN PATIENTS WITH PEPTIC ULCER</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a"><strong<Abstract. </strong<Ulcer disease is accompanied by all immune responses with the development of secondary immune deficiency. We studied 92 males with peptic ulcer having positive tests for Helicobacter pylori (24 gastric ulcer, mean age 44,7±1,97 and 68 duodenal ulcer, mean age 31,5±1,71). A half of the patients used only basis antiulcer treatment. 46 patients used bestim in the dose100 mcg per day intramusculare for a 5 days with antisecretory and antihelicobacter drugs. The addition of bestim normalized cellular immunity: count of T-lymphocytes rose from 20,52±0,89% to 31,4±1,16% (p&lt;0,05; confidence interval [CI]: 2,67-11,63). A positive trend in the number of T-lymphocytes was accompanied with increasing of T-helpers from 17,33±0,89% to 24,82±1,11% (p&lt;0,05; 95%CI: 1,72-8,47). In the course of the treatment we observed normalization of monocytes number, an increase of neutrophils activity in blood (p&lt;0,05; 95%CI: 2,35-15,64). We demonstrated decrease in IL-8 production and increase in IFN gamma production. Thus, the application of a new drug Bestim in the combined antiulcer treatment affects the immune state of the patients favourably. It decreases the inflammatory effect in the stomach and duodenal mucosa, it precipitate regress of clinical symptoms and healing of the ulcer.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Bestim</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">immunity</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Т–helpers</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Helicobacter pylori</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">gastric ulcer disease</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Immunologic diseases. Allergy</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">A. I. Dolgushina</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">K. V. Nikushina</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">A. S. Simbirtsev</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Медицинская иммунология</subfield><subfield code="d">St. Petersburg branch of the Russian Association of Allergologists and Clinical Immunologists, 2015</subfield><subfield code="g">7(2014), 5–6, Seite 611-616</subfield><subfield code="w">(DE-627)1735558133</subfield><subfield code="x">2313741X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:7</subfield><subfield code="g">year:2014</subfield><subfield code="g">number:5–6</subfield><subfield code="g">pages:611-616</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.15789/1563-0625-2005-5–6-611-616</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/d573419000114b45bf6a45334ccfce5a</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://mimmun.ru/index.php/mimmun/article/view/653</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1563-0625</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2313-741X</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">7</subfield><subfield code="j">2014</subfield><subfield code="e">5–6</subfield><subfield code="h">611-616</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	A. G. Tkacheva
spellingShingle	A. G. Tkacheva misc RC581-607 misc Bestim misc immunity misc Т–helpers misc Helicobacter pylori misc gastric ulcer disease misc Immunologic diseases. Allergy IMMUNOMODULATORY EFFECTS OF BESTIM IN PATIENTS WITH PEPTIC ULCER
authorStr	A. G. Tkacheva
ppnlink_with_tag_str_mv	@@773@@(DE-627)1735558133
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	RC581-607
illustrated	Not Illustrated
issn	2313741X
topic_title	RC581-607 IMMUNOMODULATORY EFFECTS OF BESTIM IN PATIENTS WITH PEPTIC ULCER Bestim immunity Т–helpers Helicobacter pylori gastric ulcer disease
topic	misc RC581-607 misc Bestim misc immunity misc Т–helpers misc Helicobacter pylori misc gastric ulcer disease misc Immunologic diseases. Allergy
topic_unstemmed	misc RC581-607 misc Bestim misc immunity misc Т–helpers misc Helicobacter pylori misc gastric ulcer disease misc Immunologic diseases. Allergy
topic_browse	misc RC581-607 misc Bestim misc immunity misc Т–helpers misc Helicobacter pylori misc gastric ulcer disease misc Immunologic diseases. Allergy
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Медицинская иммунология
hierarchy_parent_id	1735558133
hierarchy_top_title	Медицинская иммунология
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)1735558133
title	IMMUNOMODULATORY EFFECTS OF BESTIM IN PATIENTS WITH PEPTIC ULCER
ctrlnum	(DE-627)DOAJ00064529X (DE-599)DOAJd573419000114b45bf6a45334ccfce5a
title_full	IMMUNOMODULATORY EFFECTS OF BESTIM IN PATIENTS WITH PEPTIC ULCER
author_sort	A. G. Tkacheva
journal	Медицинская иммунология
journalStr	Медицинская иммунология
callnumber-first-code	R
lang_code	rus
isOA_bool	true
recordtype	marc
publishDateSort	2014
contenttype_str_mv	txt
container_start_page	611
author_browse	A. G. Tkacheva A. I. Dolgushina K. V. Nikushina A. S. Simbirtsev
container_volume	7
class	RC581-607
format_se	Elektronische Aufsätze
author-letter	A. G. Tkacheva
doi_str_mv	10.15789/1563-0625-2005-5–6-611-616
author2-role	verfasserin
title_sort	immunomodulatory effects of bestim in patients with peptic ulcer
callnumber	RC581-607
title_auth	IMMUNOMODULATORY EFFECTS OF BESTIM IN PATIENTS WITH PEPTIC ULCER
abstract	<strong<Abstract. </strong<Ulcer disease is accompanied by all immune responses with the development of secondary immune deficiency. We studied 92 males with peptic ulcer having positive tests for Helicobacter pylori (24 gastric ulcer, mean age 44,7±1,97 and 68 duodenal ulcer, mean age 31,5±1,71). A half of the patients used only basis antiulcer treatment. 46 patients used bestim in the dose100 mcg per day intramusculare for a 5 days with antisecretory and antihelicobacter drugs. The addition of bestim normalized cellular immunity: count of T-lymphocytes rose from 20,52±0,89% to 31,4±1,16% (p<0,05; confidence interval [CI]: 2,67-11,63). A positive trend in the number of T-lymphocytes was accompanied with increasing of T-helpers from 17,33±0,89% to 24,82±1,11% (p<0,05; 95%CI: 1,72-8,47). In the course of the treatment we observed normalization of monocytes number, an increase of neutrophils activity in blood (p<0,05; 95%CI: 2,35-15,64). We demonstrated decrease in IL-8 production and increase in IFN gamma production. Thus, the application of a new drug Bestim in the combined antiulcer treatment affects the immune state of the patients favourably. It decreases the inflammatory effect in the stomach and duodenal mucosa, it precipitate regress of clinical symptoms and healing of the ulcer.
abstractGer	<strong<Abstract. </strong<Ulcer disease is accompanied by all immune responses with the development of secondary immune deficiency. We studied 92 males with peptic ulcer having positive tests for Helicobacter pylori (24 gastric ulcer, mean age 44,7±1,97 and 68 duodenal ulcer, mean age 31,5±1,71). A half of the patients used only basis antiulcer treatment. 46 patients used bestim in the dose100 mcg per day intramusculare for a 5 days with antisecretory and antihelicobacter drugs. The addition of bestim normalized cellular immunity: count of T-lymphocytes rose from 20,52±0,89% to 31,4±1,16% (p<0,05; confidence interval [CI]: 2,67-11,63). A positive trend in the number of T-lymphocytes was accompanied with increasing of T-helpers from 17,33±0,89% to 24,82±1,11% (p<0,05; 95%CI: 1,72-8,47). In the course of the treatment we observed normalization of monocytes number, an increase of neutrophils activity in blood (p<0,05; 95%CI: 2,35-15,64). We demonstrated decrease in IL-8 production and increase in IFN gamma production. Thus, the application of a new drug Bestim in the combined antiulcer treatment affects the immune state of the patients favourably. It decreases the inflammatory effect in the stomach and duodenal mucosa, it precipitate regress of clinical symptoms and healing of the ulcer.
abstract_unstemmed	<strong<Abstract. </strong<Ulcer disease is accompanied by all immune responses with the development of secondary immune deficiency. We studied 92 males with peptic ulcer having positive tests for Helicobacter pylori (24 gastric ulcer, mean age 44,7±1,97 and 68 duodenal ulcer, mean age 31,5±1,71). A half of the patients used only basis antiulcer treatment. 46 patients used bestim in the dose100 mcg per day intramusculare for a 5 days with antisecretory and antihelicobacter drugs. The addition of bestim normalized cellular immunity: count of T-lymphocytes rose from 20,52±0,89% to 31,4±1,16% (p<0,05; confidence interval [CI]: 2,67-11,63). A positive trend in the number of T-lymphocytes was accompanied with increasing of T-helpers from 17,33±0,89% to 24,82±1,11% (p<0,05; 95%CI: 1,72-8,47). In the course of the treatment we observed normalization of monocytes number, an increase of neutrophils activity in blood (p<0,05; 95%CI: 2,35-15,64). We demonstrated decrease in IL-8 production and increase in IFN gamma production. Thus, the application of a new drug Bestim in the combined antiulcer treatment affects the immune state of the patients favourably. It decreases the inflammatory effect in the stomach and duodenal mucosa, it precipitate regress of clinical symptoms and healing of the ulcer.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	5–6
title_short	IMMUNOMODULATORY EFFECTS OF BESTIM IN PATIENTS WITH PEPTIC ULCER
url	https://doi.org/10.15789/1563-0625-2005-5–6-611-616 https://doaj.org/article/d573419000114b45bf6a45334ccfce5a http://mimmun.ru/index.php/mimmun/article/view/653 https://doaj.org/toc/1563-0625 https://doaj.org/toc/2313-741X
remote_bool	true
author2	A. I. Dolgushina K. V. Nikushina A. S. Simbirtsev
author2Str	A. I. Dolgushina K. V. Nikushina A. S. Simbirtsev
ppnlink	1735558133
callnumber-subject	RC - Internal Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.15789/1563-0625-2005-5–6-611-616
callnumber-a	RC581-607
up_date	2024-07-03T15:46:41.186Z
_version_	1803573370489405440
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ00064529X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230310194208.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230225s2014 xx \|\|\|\|\|o 00\| \|\|rus c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.15789/1563-0625-2005-5–6-611-616</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ00064529X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJd573419000114b45bf6a45334ccfce5a</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC581-607</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">A. G. Tkacheva</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">IMMUNOMODULATORY EFFECTS OF BESTIM IN PATIENTS WITH PEPTIC ULCER</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a"><strong<Abstract. </strong<Ulcer disease is accompanied by all immune responses with the development of secondary immune deficiency. We studied 92 males with peptic ulcer having positive tests for Helicobacter pylori (24 gastric ulcer, mean age 44,7±1,97 and 68 duodenal ulcer, mean age 31,5±1,71). A half of the patients used only basis antiulcer treatment. 46 patients used bestim in the dose100 mcg per day intramusculare for a 5 days with antisecretory and antihelicobacter drugs. The addition of bestim normalized cellular immunity: count of T-lymphocytes rose from 20,52±0,89% to 31,4±1,16% (p&lt;0,05; confidence interval [CI]: 2,67-11,63). A positive trend in the number of T-lymphocytes was accompanied with increasing of T-helpers from 17,33±0,89% to 24,82±1,11% (p&lt;0,05; 95%CI: 1,72-8,47). In the course of the treatment we observed normalization of monocytes number, an increase of neutrophils activity in blood (p&lt;0,05; 95%CI: 2,35-15,64). We demonstrated decrease in IL-8 production and increase in IFN gamma production. Thus, the application of a new drug Bestim in the combined antiulcer treatment affects the immune state of the patients favourably. It decreases the inflammatory effect in the stomach and duodenal mucosa, it precipitate regress of clinical symptoms and healing of the ulcer.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Bestim</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">immunity</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Т–helpers</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Helicobacter pylori</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">gastric ulcer disease</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Immunologic diseases. Allergy</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">A. I. Dolgushina</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">K. V. Nikushina</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">A. S. Simbirtsev</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Медицинская иммунология</subfield><subfield code="d">St. Petersburg branch of the Russian Association of Allergologists and Clinical Immunologists, 2015</subfield><subfield code="g">7(2014), 5–6, Seite 611-616</subfield><subfield code="w">(DE-627)1735558133</subfield><subfield code="x">2313741X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:7</subfield><subfield code="g">year:2014</subfield><subfield code="g">number:5–6</subfield><subfield code="g">pages:611-616</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.15789/1563-0625-2005-5–6-611-616</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/d573419000114b45bf6a45334ccfce5a</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://mimmun.ru/index.php/mimmun/article/view/653</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1563-0625</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2313-741X</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">7</subfield><subfield code="j">2014</subfield><subfield code="e">5–6</subfield><subfield code="h">611-616</subfield></datafield></record></collection>
score	7.402793

Nicht das Richtige dabei?

Schreiben Sie uns!

IMMUNOMODULATORY EFFECTS OF BESTIM IN PATIENTS WITH PEPTIC ULCER

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?